THE BICTON GARDENS COUNTRYSIDE MUSEUM: A GUIDE TO THE PRINCIPAL EXHIBITSJAMES N. D. G.1975, 24 p.Book

A digitally implemented QPSK modem operating at up to 10 Mbit/sJAMES, N. D.GEC journal of research. 1989, Vol 7, Num 1, pp 8-15, issn 0264-9187, 8 p.Article

Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerPARKER, C; NILSSON, S; WIDMARK, A et al.The New England journal of medicine. 2013, Vol 369, Num 3, pp 213-223, issn 0028-4793, 11 p.Article

CD40 expression in prostate cancer: A potential diagnostic and therapeutic moleculePALMER, D. H; HUSSAIN, S. A; GANESAN, R et al.Oncology reports. 2004, Vol 12, Num 4, pp 679-682, issn 1021-335X, 4 p.Article

A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancerHUSSAIN, S. A; MOFFITT, D. D; GLAHOLM, J. G et al.Annals of oncology. 2001, Vol 12, Num 7, pp 929-935, issn 0923-7534Article

CD40 expression in bladder cancerCOOKE, P. W; JAMES, N. D; GANESAN, R et al.Journal of pathology. 1999, Vol 188, Num 1, pp 38-43, issn 0022-3417Article

Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinomaSHIMWELL, N. J; BRYAN, R. T; WEI, W et al.British journal of cancer. 2013, Vol 108, Num 9, pp 1854-1861, issn 0007-0920, 8 p.Article

Hepatocellular carcinomaHUSSAIN, S. A; FERRY, D. R; EL-GAZZAZ, G et al.Annals of oncology. 2001, Vol 12, Num 2, pp 161-172, issn 0923-7534Article

A phase ii study of the bispecific antibody MDX-H210 (anti-her2×cd64) with GM-CSF in HER2+ advanced prostate cancerJAMES, N. D; ATHERTON, P. J; JONES, J et al.British journal of cancer. 2001, Vol 85, Num 2, pp 152-156, issn 0007-0920Article

Who should follow up cancer patients? Nurse specialist based outpatient care and the introduction of a phone clinic systemJAMES, N. D; GUERRERO, D; BRADA, M et al.Clinical oncology (Springer. Print). 1994, Vol 6, Num 5, pp 283-287, issn 0936-6555Conference Paper

Chondroitin sulphate proteoglycans: Key modulators of spinal cord and brain plasticity : PLASTICITY AFTER SCIBARTUS, K; JAMES, N. D; BOSCH, K. D et al.Experimental neurology (Print). 2012, Vol 235, Num 1, pp 5-17, issn 0014-4886, 13 p.Article

Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancerHUSSAIN, S. A; GANESAN, R; JAMES, N. D et al.British journal of cancer. 2007, Vol 96, Num 1, pp 104-109, issn 0007-0920, 6 p.Article

BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladderHUSSAIN, S. A; GANESAN, R; HILLER, L et al.Oncology reports. 2003, Vol 10, Num 3, pp 571-576, issn 1021-335X, 6 p.Article

Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer : Construction and testing of a tissue-specific adenovirus vectorLATHAM, J. P. F; SEARLE, P. F; MAUTNER, V et al.Cancer research (Baltimore). 2000, Vol 60, Num 2, pp 334-341, issn 0008-5472Article

Neurodegenerative changes including altered tau phosphorylation and neurofilament immunoreactivity in mice transgenic for the serine/threonine kinase mosJAMES, N. D; DAVIS, D. R; SINDON, J et al.Neurobiology of aging. 1996, Vol 17, Num 2, pp 235-242, issn 0197-4580, 7 p.Article

Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancerHUSSAIN, S. A; STOCKEN, D. D; PEAKE, D. R et al.British journal of cancer. 2004, Vol 90, Num 11, pp 2106-2111, issn 0007-0920, 6 p.Article

A National audit of radiotherapy in head and neck CancerJAMES, N. D; ROBERTSON, G; SQUIRE, C. J et al.Clinical oncology (Springer. Print). 2003, Vol 15, Num 2, pp 41-46, issn 0936-6555, 6 p.Article

Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapyCOOKE, P. W; JAMES, N. D; GANESAN, R et al.BJU international (Papier). 2000, Vol 85, Num 7, pp 829-835, issn 1464-4096Article

Long-term risk of Salvage cystectomy after radiotherapy for muscle-invasive bladder cancer. CommentaryCOOKE, P. W; DUNN, J. A; LATIEF, T et al.European urology. 2000, Vol 38, Num 3, pp 279-286, issn 0302-2838Article

Liposomal doxorubicin (doxil): an effective new treatment for Kaposi's sarcoma in AIDSJAMES, N. D; COKER, R. J; TOMLINSON, D et al.Clinical oncology (Springer. Print). 1994, Vol 6, Num 5, pp 294-296, issn 0936-6555Conference Paper

Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potentialBRYAN, R. T; SHIMWELL, N. J; WEI, W et al.British journal of cancer. 2014, Vol 110, Num 3, pp 679-685, issn 0007-0920, 7 p.Article

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancerROSSI, J.-F; NEGRIER, S; JAMES, N. D et al.British journal of cancer. 2010, Vol 103, Num 8, pp 1154-1162, issn 0007-0920, 9 p.Article

A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancerHUSSAIN, S. A; STOCKEN, D. D; RILEY, P et al.British journal of cancer. 2004, Vol 91, Num 5, pp 844-849, issn 0007-0920, 6 p.Article

Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladderHUSSAIN, S. A; GANESAN, R; HILLER, L et al.British journal of cancer. 2003, Vol 88, Num 4, pp 586-592, issn 0007-0920, 7 p.Article

Outcome of children with resistant and relapsed Hodgkin's diseaseJAMES, N. D; KINGSTON, J. E; PLOWMAN, P. N et al.British journal of cancer. 1992, Vol 66, Num 6, pp 1155-1158, issn 0007-0920Article